Printer Friendly

Pacific Biometrics, Inc. Presents Amplification Technology at Experimental Biology 2003.

Business Editors & Health/Medical Writers

Experimental Biology 2003

SEATTLE--(BUSINESS WIRE)--April 25, 2003

Pacific Biometrics, Inc. (PBI) (OTCBB:PBME) announced today that it made its first public presentation of its proprietary DNA amplification technology (LIDA) at the Experimental Biology 2003 meeting in San Diego, California.

PBI gave a presentation entitled "A novel isothermal target amplification strategy based on deoxynucleotide-containing intermediate transcription products." The presentation was on PBI's Logarithmic Isothermal DNA Amplification (LIDA) technology. Highlights of the presentation included LIDA's speed, specificity, and use with real-time detection chemistries.

"Experimental Biology 2003 is the perfect place to present LIDA," commented Ron Helm, Chief Executive Officer at PBI. "This meeting represents an opportunity to showcase LIDA's abilities to a large international group of scientists and companies."

Experimental Biology 2003 was held from April 11-15 at the San Diego Convention Center and boasted over 12,000 scientists from all over the world. Contributions from the American Association of Anatomists, American Physiological Society, American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, American Society for Nutritional Sciences, American Society for Pharmacology and Experimental Therapeutics, and various guest societies rounded out the program.

About Pacific Biometrics, Inc.

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, osteoporosis, diabetes, and nutrition. The PBI laboratory is accredited by the College of American Pathologists and is one of only five U.S.-based labs fully approved and accredited by the Center for Disease Control (CDC) as a Cholesterol Reference Lab. Clients for PBI include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

As part of a recent asset purchase agreement with Saigene Corporation, Pacific Biometrics owns several patented and patent-pending technologies, including an advanced, proprietary, isothermal DNA amplification assay, and gene-based tests involved in sterility testing and antibiotic susceptibility testing.

For more information about Pacific Biometrics, visit the company's website at www.pacbio.com or contact Ronald Helm, Chairman/CEO at 206/298-0068.

Certain statements contained in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results and outcomes may differ materially from those discussed or anticipated. Factors that might affect the actual outcome include, but are not limited to, our problems of operating with a history of losses and an accumulated deficit, our potential liquidity problems since historically we have not been able to generate positive cash flow, our ability to raise additional capital and the likelihood that it may not be secured, our difficulties of competing in the biotechnology industry which is subject to rapid changes, our potential difficulties of protecting our patents and other proprietary rights and potential intellectual property claims against us, general competition and technological changes, the possible cancellation of our existing or future contracts, our future growth prospects, and changes in our management. For a more detailed discussion of risk factors, see the company's most recent documents filed with the Securities and Exchange Commission.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 25, 2003
Words:525
Previous Article:Frequent Flyers Rate Alaska Best Overall Program, Best Web Site and Best Redemption Award.
Next Article:Encore Wire Corporation Q1 Conference Call Announcement.


Related Articles
Academic Achievement in Introductory Biology: The Relationship of Student Variables. (Science Education Section).
Pacific Biometrics, Inc. Establishes New Technology Subsidiary; PBI Technology, Inc. to Address Market Demand in Molecular Diagnostic Technologies.
Widespread null alleles and poor cross-species amplification of microsatellite DNA loci cloned from the Pacific oyster, Crassostrea gigas.
DNA amplification: current technologies and applications.
Pacific Biometrics to Present at the PIPEs Conference 2005 on October 26th and 27th.
Webcast Alert: Pacific Biometrics, Inc. Presentation at The PIPEs Conference 2005 to be Webcast on Wednesday, October 26, 9:30am EST.
Pacific Biometrics, Inc.'s Chief Scientific Officer, Dr. Elizabeth Leary, to Present New Assay at Annual KinMet Satellite Symposium; New ELISA assay...
Improving students' understanding and perception of cell theory in school biology using a computer-based instruction simulation program.
QIAGEN UNVEILS FAST CYCLING PCR TECHNOLOGY.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters